Raveron versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH).
Thirty patients with BPH were randomized into two groups to receive Raveron and placebo for 6 weeks. The subjective and objective signs associated with BPH were evaluated before and after treatment. There was no significant difference between the effects of Raveron and placebo.